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Abstract 
Tumour microenvironment greatly influences the development and metastasis of cancer 
progression. The development of three dimensional (3D) culture models which mimic that 
displayed in vivo can improve cancer biology studies and accelerate novel anticancer drug 
screening. Inspired by a systems biology approach, we have formed 3D in vitro 
bioengineered tumour angiogenesis microenvironments within a glycosaminoglycan-based 
hydrogel culture system. This microenvironment model can routinely recreate breast and 
prostate tumour vascularisation. The multiple cell types cultured within this model were less 
sensitive to chemotherapy when compared with two dimensional (2D) cultures, and displayed 
comparative tumour regression to that displayed in vivo. These features highlight the use of 
our in vitro culture model as a complementary testing platform in conjunction with animal 
models, addressing key reduction and replacement goals of the future. We anticipate that this 
biomimetic model will provide a platform for the in-depth analysis of cancer development 
and the discovery of novel therapeutic targets.  
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1. Introduction 
Innovative medical and materials research has led to novel technologies in the quest for 
improved cell culture methods. Pioneering research in three dimensional (3D) culture models 
from the Bissell laboratory [1] has opened the way for more sophisticated and relevant 
culture models than the traditional two dimensional (2D) methods. Although 2D methods 
have contributed unsurmountable medical breakthroughs in cancer research and drug 
discovery, the progression of cancer to an advanced state cannot be recapitulated in 2D and 
moreover cannot be completely understood from small animal models. Therefore it is 
imperative that we close the gap between poorly instructive 2D cultures and the often less 
descriptive and already too complex small animal models. This will lead towards a more 
detailed understanding of cancer progression using a far more adaptable and relevant 
physiological systems biology approach [2].   
Tumour growth and development is dependent on the surrounding microenvironment, 
including the extracellular matrix (ECM), cell-cell contacts and environmental cues [3, 4]. 
Cellular interactions and growth factor signalling are known to regulate cancer development, 
including tumour angiogenesis [5, 6]. However, little information is available to study the 
tumour microenvironment with respect to the vascularisation in vitro. Attempts to mimic 
tumour angiogenesis in vitro by means of co-cultivation or using layered synthetic materials 
have had limited success, as current methodologies are insufficient to support and maintain 
all cellular types in culture [7], and the outcomes of the culture model are most likely 
dependent on how much of the microenvironment is actually recapitulated within the 
bioengineered construct.  
Only a few research groups have attempted breast or prostate tumour-vasculature co-
culture, and show varying results. A recent report utilised MDA-MB-231 breast cancer cells 
co-cultured with human umbilical vein endothelial cells (HUVECs) and normal human 
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dermal fibroblasts to mimic in vivo tumour-vasculature interactions within collagen type I 
gels [8]. In another report, collagen I and fibrinogen gels were utilised for a co-culture model 
with PC3 prostate cancer cells, as well as HUVECs and human foreskin fibroblasts [9]. One 
problem arising from these approaches is that such natural matrices can result in batch-to-
batch variability, inherent cellular signalling molecules, degradation, shrinkage, difficulties in 
the ability to monitor the culture progression and a general lack of mechanical stability which 
can have unknown effects on cancer cell biology and development.  
To address these challenges, we have developed matrix metalloproteinase (MMP)-
sensitive four-arm star-shaped poly(ethylene glycol) (starPEG)-heparin hydrogels [10, 11] in 
which RGD motifs are incorporated at a defined density. The RGD motifs provide binding 
sites for cells via integrins, and the MMP-responsive sequences allow cells to locally remodel 
the matrix for the purposes of proliferation and migration. The materials can be readily 
fashioned into a hydrogel structure and can be tuned to the particular requirements of the 
tumour microenvironment via the precise adjustment of stiffness and mesh size. Furthermore, 
decoration with various growth factors and ECM protein-based cues is possible, utilising the 
signal molecule affine glycosaminoglycan heparin as a bioactive building block. We have 
previously shown that these starPEG-heparin hydrogels provide an effective matrix for the 
co-culture of hepatocarcinoma cells with HUVECs[12].  
Herein, we established a highly sophisticated and complex 3D microenvionment of 
human cancer angiogenesis by culturing breast or prostate epithelial carcinoma cells (MCF-7, 
MDA-MB-231, LNCaP, PC3) with HUVECs and mesenchymal stromal cells (MSCs) within 
matrices fabricated from synthetic starPEG and maleimide-functionalised heparin (Fig. 1). 
This study is conducted in three stages: comparative evaluation of cancer tumour growth 
within starPEG-heparin hydrogels and within Matrigel
TM
, evaluation of the bioengineered 
 5 
tumour angiogenesis microenvironment, and evaluation of the responsiveness of the culture 
model to chemotherapeutics and angiogenesis inhibitors.  
 
2. Materials and Methods 
2.1. Cell culture.  
MCF-7, MDA-MB-231 and LNCaP cell lines were obtained from the Deutsche Sammlung 
von Mikroorganismen und Zellkulturen (DSMZ; Braunschweig, Germany) and used within 
10 passages. The PC3 cell line was obtained from the American Type Culture Collection 
(ATCC; LGC Standards GmbH, Wesel, Germany), authenticated by the DSMZ and used for 
experiments within 10 passages. MCF-7 cells were cultured in medium consisting of RPMI 
medium supplemented with GlutaMax (Life Technologies, Darmstadt, Germany), 10 % fetal 
bovine serum (FBS; Hyclone Thermo Scientific, Schwerte, Germany), 1X MEM non-
essential amino acids (Life Technologies), 1 mM Sodium Pyruvate (Sigma Aldrich, Munich, 
Germany), 0.1 % human insulin (Life Technologies) and 1 % penicillin/streptomycin solution 
(PS; Life Technologies). MDA-MB-231 cells were cultivated in DMEM supplemented with 
10 % FBS and 1 % PS. LNCaP and PC3 cells were propagated in RPMI medium 
supplemented with 10 % FBS and 1 % PS. HUVECs were isolated as previously described 
[13] and cultured in Endothelial Cell Growth Medium (ECGM; Promocell, Heidelberg, 
Germany). Bone marrow-derived MSC were isolated as previously described [14] and 
cultured in DMEM supplemented with 10 % FBS and 1 % PS. HUVECs and MSCs were 
utilised for experiments between passages 1 and 6. 
 
2.2. Preparation of tumour constructs.  
Hydrogels were prepared as described previously [11]. The heparin batch was modified with 
an average of 6 maleimide groups per molecule of heparin. MCF-7, MDA-MD-231, LNCaP 
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or PC3 cells at a density of 5 × 10
5
/mL were seeded separately into non-functionalised 
starPEG-heparin hydrogels for tumour only experiments utilising gels at a crosslinking 
degree of γ0.75, γ1.0 or γ1.5 (molar ratio of starPEG to heparin-maleimide), which vary in 
stiffness from 500 – 3000 Pa. For tumour angiogenesis cultures, the heparin-maleimide 
fraction of the hydrogel was first functionalised with 2 moles of RGD-SP (H2N-
GCWGGRGDSP-CONH2; MW 990; synthesised within our laboratory) per mole of heparin 
and vortexed thoroughly. 5 μg/mL of each vascular endothelial growth factor (VEGF; 
Peprotech, Hamburg, Germany), fibroblast growth factor 2 (FGF-2) and stromal cell-derived 
factor 1 (SDF-1; both Miltenyi Biotec, Bergisch Gladbach, Germany) were then added to the 
heparin-maleimide solution. Cancer cell lines were afterwards seeded at a density of 2.5 × 
10
5
 /mL in combination with 6 × 10
6
 HUVECs and 6 × 10
5
 MSCs per mL of gel for tumour 
angiogenesis experiments, into the heparin fraction. For all tumour angiogenesis tri-culture 
experiments, the heparin-maleimide-cell suspension was mixed with the starPEG solution 
(1:1 volume ratio) to create a γ0.63, 200-300 Pa hydrogel. Alternatively, hydrogels 
containing tumours cultivated for 7-10 days were harvested using 2 mg/mL collagenase 
(SERVA, Heidelberg, Germany), centrifuged and resuspended in phosphate buffered saline 
(PBS; Life Technologies) to combine in a new hydrogel co-culture with HUVECs and MSCs. 
Afterwards, the components were mixed by pipetting, and a 20 μl gel was cast onto a 
microscope slide coated with Sigmacote
®
 (Sigma Aldrich). Tumour only constructs were 
grown for 14 days as floating droplets in medium suitable for each cell type. Tumour 
angiogenesis tri-cultures were grown in ECGM for 14 days before fixation with 4 % 
paraformaldehyde. Matrigel
TM
 (BD Biosciences, Heidelberg, Germany) or TCP was used as a 
control for all hydrogel experiments. Light microscopy images were analysed using Image J. 
 
2.3. PrestoBlue Assay.  
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A 1:10 dilution of PrestoBlue Reagent (Life Technologies) in serum-free media was applied 
to each sample in a volume of 300 µl per well in a 24-well plate. Samples were incubated for 
40 min at 37 °C before 100 µl of solution was aliquoted in duplicate into a black 96-well 
plate. Fluorescence was detected using a Tecan GENios plate reader (Tecan Deutschland 
GmbH, Mainz-Kastel, Germany) at a wavelength of 590 nm. 
 
2.4. Immunostaining.  
After fixation, cultures were washed in PBS and then directly immunostained or embedded in 
OCT solution overnight in the fridge. Samples were then snap-frozen on dry ice. Hypoxia 
was localised using the Hypoxyprobe-1 kit (International Clinical Services GmbH, Munich, 
Germany) by adding 100 μM pimonidazole hydrochloride to the cell media in culture for 4 
hours. Sectioned samples were treated with 2 mg/mL Collagenase (SERVA, Heidelberg, 
Germany) in PBS briefly before samples were blocked and permeabilised using 5 % goat 
serum and 0.1 % Triton X-100 in PBS. Antibody expression against CD31 (BD Biosciences), 
Von Willebrand Factor (Dako, Hamburg, Germany), E-Cadherin (Biolegend, Fell, Germany), 
Ki67 and CK8 (both Dianova, Hamburg, Germany) was detected using a dilution of 1:100 of 
primary antibody incubated overnight at 4 ˚C. After washing, a secondary Alexa fluor 488 
goat anti-mouse or anti-rabbit antibody (Life Technologies) was applied to the samples at a 
1:200 dilution in combination with Phalloidin Alexa Fluor 633 (1:50 dilution; Life 
Technologies) overnight at 4˚C. Afterwards, samples were washed and incubated with 
Hoechst 33342 nuclear dye (Life Technologies) at a concentration of 1 ng/mL for 30 minutes 
before visualisation on a Leica Confocal SP5 microscope (Leica Mikrosysteme Vertrieb 
GmbH, Wetzlar, Germany). Image analysis was performed using Velocity 3D Image 
Analysis Software v6.3 (PerkinElmer, Hamburg, Germany). 
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2.5. Atomic force microscopy (AFM).  
AFM measurements were performed using a Nanowizard II AFM (JPK Instruments, Berlin, 
Germany) mounted on an inverted optical microscope (Observer.D1, Zeiss). Measurements 
were conducted at 37 °C using a PetriDishHeater (JPK Instruments) sample chamber. Tipless 
silicon nitride cantilever with a nominal spring constant of 80 mN*m
-1
 (PNP-TR-TL-Au; 
Nanoworld) were used. Cantilevers were modified with silica beads (10µm, Kisker Biotec 
GmBH) as described [15]. Spring constants were calibrated before measurements using the 
equipartition theorem [16]. Force-distance curves were acquired in closed loop, constant 
height mode using 3 nN contact force and 5 μm/s approach/retract velocity. Each data set was 
generated by probing a minimum of 70 different spots on each sample. The data processing 
software provided by the AFM manufacturer (JPK Instruments) was used to extract the 
Young’s Modulus E from approach force–distance curves. 
 
2.6. Chemotherapy treatment.  
Single cell cultures of cancer cells and tri-cultures were prepared as described above in 
starPEG-heparin hydrogels. Cultures were grown for 7 days in 3D culture, or for 2 days in 
2D culture, after which a PrestoBlue assay was performed (day 0). Doxorubicin was added at 
0, 8, 20, 40, 200, 2000 or 4000 ng/mL to LNCaP or PC3 2D, 3D tumour only and tumour 
angiogenesis tri-cultures. Epirubicin was added at 0, 8, 20, 40, 200, 2000 or 4000 ng/mL to 
MCF-7 or MDA-MB-231 2D, 3D tumour only and tumour angiogenesis tri-cultures. 
Paclitaxel was added at 0, 0.1, 1, 5, 20, 100 or 500 nM to all 2D, 3D tumour only and tumour 
angiogenesis tri-cultures. All drugs were incubated for 24 hours in ECGM before a media 
change occurred. PrestoBlue assays and photodocumentation were performed 3 and 5 days 
post-treatment. DMSO was used at the highest relative concentration as a carrier control for 
paclitaxel experiments. 
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2.7. Angiogenesis inhibitor treatment.  
Tumour only 3D cultures and tumour angiogenesis tri-cultures were prepared as described 
above in starPEG-heparin hydrogels. Cultures were grown for 7 days in 3D culture after 
which a PrestoBlue assay was performed (day 0). 3D tumour only cultures were first tested 
for growth hindrance from the angiogenesis inhibitors. Axitinib (Sigma Aldrich) or SU-5402 
(Sigma Aldrich) was added to cultures at 2.5 μM. AMD3100 (Sigma Aldrich) was added to 
cultures at 10 μg/mL. Cultures were treated for 48 hours with each angiogenesis inhibitor, 
after which a media change occurred. A PrestoBlue assay was performed to measure 
metabolic activity 5 days post-treatment. Tumour angiogenesis tri-cultures were also treated 
with the angiogenesis inhibitors at day 0 of culture or at day 7 of culture to visualise hindered 
development of angiogenesis or disruption of formed vascular networks. Cultures were 
visualised by photodocumentation using a light microscope. 
 
2.8. Statistical analysis.  
All statistics were performed using GraphPad Prism v6. Data was assessed using a two-way 
analysis of variance (ANOVA) with post-hoc Tukey’s multiple comparisons tests.  Student t-
test analyses were performed on individual chemotherapy doses to determine significant 
differences between cohorts. Significance is reported as * (p<0.05), ** (p<0.01), *** 
(p<0.001) or **** (p<0.0001). 
 
3. Results 
3.1. 3D breast and prostate tumour only culture models.  
We engineered tumour models by culturing MCF-7, MDA-MB-231, LNCaP and PC3 cells 
within non-functionalised starPEG-heparin hydrogels of varying stiffness from 
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approximately 500 Pa to 3000 Pa (Supplementary Fig. 1). Gels of a crosslinking degree of 
γ1 (starPEG to heparin molar ratio) that were approximately 1500 Pa in stiffness were most 
optimal for handling, spheroid formation and cellular proliferation, therefore this was utilised 
for all subsequent tumour only experiments. A direct comparison of 2D and 3D growth was 
performed by seeding 1.5 × 10
4
 cells into either a single hydrogel or a single well of a 24-
well plate. Breast and prostate cancer cell culture within the hydrogel system more closely 
mimicked the slower growth profile of natural tumour growth than the rapid proliferation 
displayed in 2D using tissue culture plastic (TCP) (Fig. 2A and 2B). An increase in 3D 
tumour cell proliferation in comparison to 2D growth was visualised at day 14, however this 
is most likely due to the TCP well already achieving confluency at this point. Over time, 
hypoxic areas formed in the MCF-7 and LNCaP tumours as shown by pimonidazole staining 
(Fig. 2C). MCF-7, LNCaP and PC3 cells proliferated and formed spherical tumours within 
the hydrogels (Fig 3A). MDA-MB-231 cells did not display spherical tumour formation 
within Matrigel
TM
 or the hydrogel platform, while PC3 cells did not form spheres within the 
Matrigel
TM
 only. Immunostaining for the proliferative marker, Ki67 and the epithelial 
markers, E-Cadherin and CK8, were similar between cells grown in Matrigel
TM
 or in the 
starPEG-heparin hydrogels (Fig. 3B). Within MCF-7 and LNCaP spheroids, E-Cadherin 
localised within cell-cell contacts, whereas in PC3, lower levels of E-Cadherin staining were 
visualised in a more uniform distribution. E-Cadherin was not expressed in MDA-MB-231 
cells. Ki67 expression was predominantly positive in the outer regions of the tumour 
spheroids in all cell types. These results showed the feasibility of the hydrogel matrix for 
embedding and for the cultivation of tumour spheroids in 3D.  
 
3.2. Bioengineered tumour-angiogenesis model.  
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To encourage tumour angiogenesis, we pre-functionalised soft hydrogels, of approximately 
200 Pa, with the adhesion peptide, RGD, as well as pro-angiogenic factors, VEGF, FGF-2 
and SDF-1 when adding the cells before casting [12]. Little difference was distinguished after 
14 days of tri-culture between the addition of tumours which had or had not been pre-grown 
for 7-10 days before seeding into the gel with the vascular and stromal cell types (Fig. 4A). 
In both cases, small amounts of interaction were visualized between the HUVECs, and the 
tumour spheroids, as determined by immunostaining for CD31 (Fig. 4B and 4C). 
Connections between tumour and vascular cell types were predominantly towards the 
periphery of tumours rather than penetrating within. Compared with Matrigel
TM
, tumour 
angiogenesis models grown in the starPEG-heparin hydrogel system displayed a more 
ordered development of tumour angiogenesis and vascular recruitment (Fig. 4A), with clearly 
defined tumours proliferating while in connection with HUVECs. Moreover, although 
Matrigel
TM
 was able to generate HUVEC tube formation without extra growth factors, it was 
discovered that any diffusion of factors from Matrigel
TM
 itself was not enough to generate 
tube formation within HUVEC-embedded hydrogels (Supplementary Fig. 2B). The addition 
of RGD and pro-angiogenic cytokines was still necessary to generate HUVEC tube formation 
in this case.  
In order to investigate the stiffness of the tumour microenvironment after cell seeding, 
AFM was performed. After 24 hours, the tumour angiogenesis model using our hydrogel 
system had a Young’s modulus of 768.57 Pa ± 137.99 SD without cells, but significantly 
(p<0.0001) decreased to 515.53 Pa ± 158.94 SD, 472.27 Pa ± 119.22 SD Pa and 434.38 ± 
181.52 SD for MCF-7, MDA-MB-231 and PC3 tumour angiogenesis tri-culture systems 
respectively (Supplementary Fig. 2A). The LNCaP tri-culture system did not change the gel 
mechanical properties significantly (563.21 Pa ± 158.96 SD) after 24 hours.  
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3.3. Responsiveness of tumour angiogenesis model to chemotherapeutic drugs.  
As resistance to anticancer drugs represents a key characteristic of enhanced tumour 
malignancy, previously demonstrated to be altered in 3D culture [17, 18], we analysed the 
responsiveness of tumour only and tumour-angiogenesis models to chemotherapy. We treated 
2D monolayer cultures, 3D tumour only models, and 3D tumour angiogenesis models with 7 
concentrations of paclitaxel, epirubicin or doxorubicin. The average weight of our hydrogel 
tumour microenvironment construct was 35.38 mg ± 5.31 SD (n=6). All anticancer drugs 
were added to the floating hydrogel cultures within 1mL of media. Therefore, based on the 
35.38 mg gel and 1 g of solution, we calculated that 1035.38 mg was the average weight per 
experimental well. For the highest concentration of anticancer drug utilised, it can be 
determined that we used approximately 4 mg/kg of doxorubicin or epirubicin, or 0.5 mg/kg 
of paclitaxel. This is very similar to drug concentrations utilised in reported small animal 
models [19-22]. Tumour cells cultured under 2D conditions were most sensitive to the drugs 
applied when compared with the 3D tumour only or tumour angiogenesis cultures (Fig. 5 and 
Fig. 6). Significant differences were found between 2D and 3D metabolic activity after 
application of 2000 or 4000 ng/mL epirubicin at day 3 post-treatment for the MCF-7 cell line 
(p<0.01 and p<0.0001 respectively) (Fig. 5C). When comparing cellular metabolic activity to 
the untreated control, a significant reduction was not demonstrated at day 3 post-treatment for 
either breast cancer cell line cultivated in 3D (Fig. 5C), indicating higher resistance. A 
significant difference was visualised between 2D and tri-culture PC3 metabolic activity at 
500 nM paclitaxel (p<0.05) (Fig. 6C). Moreover, significant decreases in metabolic activity 
compared to the untreated control were demonstrated for PC3 3D tumour only and tumour 
angiogenesis tri-cultures. The highest concentrations of each anticancer drug also resulted in 
a reduction of tumour size of 39.47 % ± 6.24 SD (epirubicin) and 38.98 % ± 5.19 SD 
(paclitaxel) in MCF-7 cells and 24.51 % ± 14.19 SD (epirubicin) and 22.99 % ± 19.19 SD 
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(paclitaxel) in MDA-MB-231 cells (Fig. 5B). Tumour regression in the prostate cancer 3D 
model was 57.29 % ± 5.39 SD (doxorubicin) and 43.41 % ± 9.5 SD (paclitaxel) for LNCaP 
cells and 51.76 % ± 13.18 SD (doxorubicin) and 55.67 % ± 17.52 SD (paclitaxel) for PC3 
cells (Fig. 6B). Interestingly, tumour angiogenesis models also displayed slightly increased 
sensitivity to the drugs compared to the tumour only models, perhaps due to the increased 
hydrogel stiffness used for the tumour only models. Due to the tumour only models 
disintegrating within 7 days if cultured within hydrogels below 500 Pa (Supplementary Fig. 
1), γ1, 1500 Pa tumour only models, but 200 Pa tumour angiogenesis tri-culture models, were 
utilised for the chemotherapy studies. All drugs, at maximum concentration, hindered cancer 
tumour growth or disintegrated HUVEC/MSC networks (Fig. 5A and Fig. 6A). Student t-
tests denoted significant differences between 2D tumour only and 3D tri-cultures response to 
drug treatment (Table 1). MCF-7 and MDA-MB-231 3D tri-cultures displayed a significant 
increase in metabolic activity at the highest dose of epirubicin but not paclitaxel when 
compared with 2D monolayer cultures. LNCaP 3D tri-cultures displayed significant increases 
in metabolic activity at day 5 post-treatment after the addition of 4000 ng/mL doxorubicin 
and at day 3 and day 5 post-treatment after the addition of 500 nM paclitaxel when compared 
with 2D monolayers. Furthermore, PC3 cultures consistently displayed higher metabolic 
activity within the tumour angiogenesis microenvironment than in the 2D monolayer after 
drug treatment. 
 
3.4. Responsiveness of tumour angiogenesis model to angiogenesis inhibitors.  
Angiogenesis inhibitors are another method of anticancer treatment, therefore we further 
validated our tumour angiogenesis model using axitinib (VEGFR inhibitor), AMD3100 
(SDF-1R inhibitor) and SU-5402 (FGFR inhibitor). We first tested the response of tumour 
only cultures grown in 3D using the hydrogel system. Significant (p<0.01) growth inhibition 
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was detected in MCF-7 3D cultures as a result of axitinib treatment when compared with the 
untreated control (Fig. 7). Afterwards, we tested the addition of angiogenesis inhibitor 
compounds to the growth media of 3D tumour angiogenesis tri-culture models at day 0 or at 
day 7 of culture. When added at day 0, the HUVEC/MSC network was not formed under 
axitinib, whereas under AMD3100 and SU-5402 conditions some HUVEC/MSC networks 
were visualised (data not shown). Moreover, axitinib significantly decreased metabolic 
activity in all tumour angiogenesis environments when added at day 0 of culture. In MCF-7 
tumour angiogenesis tri-cultures, both AMD3100 and SU-5402 also significantly inhibited 
metabolic activity when inhibitors were added at day 0 of culture. When added at day 7, 
network breakdown was visualised after 7 days of treatment in all culture conditions, most 
predominantly in the axitinib cohort (data not shown). Significant differences (p<0.01) 
between tumour angiogenesis tri-cultures that were untreated or treated  with axitinib at day 7 
of culture were only visualised in the LNCaP model, but a similar trend was seen in all 
tumour angiogenesis models. AMD3100 and SU-5402 did not affect the metabolic activity of 
the tumour angiogenesis microenvironment. 
 
4. Discussion 
Angiogenesis is crucial for tumour growth, and how tumour angiogenesis initiates and 
develops remains largely unknown [23]. Fundamental research has typically relied on 
conventional 2D cell culture methods and on small animal models to study the complex 
mechanisms of angiogenesis. However, cell-cell and cell-matrix interactions involved during 
cancer progression in humans can hardly be reflected by these models, which hinder the 
targeted identification of more effective anticancer and antiangiogenic drugs, preventative 
measures and combination treatments. Moreover, expensive in vivo models do not fully 
replicate human biology, and can be difficult to monitor and study tumour progression 
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without animal harm or sacrifice. Recently, we have seen rapidly expanding research 
activities aimed at 3D in vitro models capable of mimicking vascular development in situ 
[24-26]. However, to fully exploit the potential of 3D microenvironment models, currently 
evolving biomaterials solutions for tissue engineering and stem cell bioengineering, as well 
as technologies for parallel cell culture, need to be adapted. Here, we present an in vitro 
human tumour angiogenesis model that exhibits microenvironmental conditions 
representative of tumours in vivo. Comparisons of tumour angiogenesis development 
engineered in our starPEG-heparin hydrogels with standard 3D Matrigel
TM
 culture indicate 
that, in some situations, tumours grown in the starPEG-heparin matrices may be more 
appropriate models to study certain aspects of cancer progression.  
As expected, the growth of all cancer cell lines was drastically reduced in 3D culture 
when compared with 2D culture methods [17, 27, 28]. When the growth of cancer spheroids 
within the hydrogel platform was directly compared with Matrigel
TM
, initially only small 
differences were visualised, however after 7 - 10 days of growth the morphology of tumour 
cells and spheres had changed. Within the hydrogel platform, the MCF-7, LNCaP and PC3 
cells displayed smooth, spherical tumours when compared with the Matrigel
TM
-grown 
cultures. The MDA-MB-231 cells did not form colonies of more than several cells within 
either material. These first results underline the more naturally instructive nature and softer 
mechanical properties of the Matrigel
TM
 and in contrast, our hydrogel platform does not 
inherently signal the tumours in a particular way, thus leading to greater control of the culture 
system. The increased stiffness and biochemical functionality of our hydrogel platform 
compared with Matrigel
TM
 may also assist in explaining the differences in cellular 
arrangement between platforms [29]. Although the morphology of the tumour spheres was 
different between the starPEG-heparin hydrogel platform and the Matrigel
TM
, the phenotype 
of the cultures remained the same.  
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Our bioengineered 3D tumour angiogenesis tri-culture model mimicked features such as 
tumour-vascular contact, similar to that hypothesised to occur within the early stages of 
tumour development [23]. In the future, studies must be pursued to mimic the complexity of a 
hetero-cellular tumour microenvironment. In considering the current results, the limitations 
of this model must also be discussed. Firstly, these experiments were performed using breast 
and prostate tumour cell lines, and primary human donor cells may provide altered responses. 
It is important also, to consider the source of vascular cell types used. HUVECs are widely 
used due to their ease of isolation and availability; however, functional tissue-specific 
vascular endothelial cells could contain different properties necessary to replicate cancer 
development.  
The majority of multi-cellular spheroids within our model were approximately 100μm, which 
is naturally too small a diameter to visualize the effect of true central hypoxic conditions on 
initial tumour angiogenesis, as the maximum diffusion limit of oxygen is approximately 100 - 
200 μm [23]. Importantly, characterisation of whole-culture immunofluorescence is possible 
within the hydrogel system due to the ability to control the size of the culture system (in this 
case, 20 μl droplets) and the lack of autofluorescence from the gels.  
Within our culture model, the 2D and 3D tumour microenvironments, as well as the 
tumour angiogenesis tri-culture model, all possessed altered responses towards 
chemotherapeutics due to the differences between 2D and 3D cell-matrix interactions, and in 
the case of the tri-culture, differences in cell-cell interactions. Our PC3 prostate tumour 
model most closely correlates with reported in vivo results. Zhang and colleagues described 
the use of 5 mg/kg doxorubicin in BALBc/nu.nu mice, which after 8 days displayed 
approximately 35 % decrease in tumour volume when compared with the control [22]. A 
similar tumour progression was reported by El-Zawahry and colleagues using 4 mg/kg 
doxorubicin in nude mice 10 days after treatment [20]. In comparison, our PC3 tumour 
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microenvironment model, after 4 mg/kg treatment displayed approximately 40 % tumour 
regression when compared with untreated controls. In some cases, our 3D models did not 
significantly decrease when exposed to the highest concentration of drugs, therefore an 
increase in treatment concentrations may expose different effects. Nonetheless, these results 
highlight the relevance of our tumour microenvironment with in vivo models and the use of 
more clinically applicable doses than in 2D culture. Another advantage of our system is the 
ability to control and investigate cellular behaviour in real time, whereas in vivo, the main 
method to identify drug efficacy is through the measurement of tumour size before and after 
animal sacrifice. Longer term cultures that allow for the study of tumour cell recovery and 
proliferation post-treatment, as in in vivo models, highlights a future prospect for 
investigation.  
Another important method for clinical breast and prostate cancer treatment, is the use 
of angiogenesis inhibitors in order to starve the tumour cells of oxygen and nutrients. 
Furthermore, it has been reported that angiogenesis inhibitors can sensitise tumours to 
chemotherapeutics [30-32], and thus combination therapies are in theory more effective. 
However, more detailed investigations of chemotherapeutic-angiogenesis inhibitor 
interactions are required in order to determine the method of tumour cell sensitisation and 
optimise combination therapies. In the current study, we utilised axitinib, a VEGFR inhibitor 
which has demonstrated clinical efficacy in phase II trials. Ma and Waxman have previously 
reported PC3 tumour suppression in a prostate cancer xenograft model due to axitinib 
treatment [30]. From daily treatment, on day 12 the axitinib-treated tumours were 
significantly smaller. In our 3D tumour microenvironment model, we saw a non-significant 
decrease in tumour growth activity when axitinib was added at day 7 to tumour only 3D 
cultures and the tumour angiogenesis tri-culture model. However, we observed a significant 
decrease in tumour angiogenesis metabolic activity when axitinib was added at day 0. It is 
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hypothesised that axitinib may impact the density of the microvessels, especially through 
decreases in microvessel size [30]. Nonetheless, although axitinib only significantly reduced 
MCF-7 tumour growth independently in our model, it is possible that there are some 
cytotoxic effects of the inhibitor on some tumour cell types.  
AMD3100 is a potent CXCR4 inhibitor. AMD3100 treatment alone has been reported 
by Domanska et al., to not affect PC3 tumour growth within an in vivo model [32]. Our 
results further compare with Cho and colleagues, who determined a non-significant 
suppression of PC3 proliferation at 1 and 10 μg/mL AMD3100 [33]. In addition, these results 
were derived from PC3 cells grown in 2D rather than in 3D. However, in a xenograft model, 
AMD3100 suppressed tumour growth in vivo by 50 % on day 7 post-treatment [33]. In our 
own model, AMD3100 had a small non-significant effect on the metabolic activity of the 
tumour angiogenesis tri-culture system when added at either day 0 or day 7 of culture.  
SU-5402, a specific tyrosine kinase inhibitor for FGFR, has been demonstrated to 
reduce HUVEC survival [34, 35]. In our tumour microenvironment model, all tumour 
angiogenesis tri-cultures also demonstrated an approximate 20 % decrease in metabolic 
activity when SU-5402 was added at day 0 of culture. However, SU-5402 did not 
demonstrate significant effects on tumour only 3D cultures or when added at day 7 of tumour 
angiogenesis tri-culture. Moreover, our results concur with Reis-Filho and colleagues who 
found SU-5402 showed no significant effects on the growth of MCF-7 cells in 2D [36]. It can 
be hypothesised that higher doses of axitinib, SU-5402 or AMD3100 could exert greater 
effects on our 3D tumour microenvironment model when compared to the higher doses 
utilised in a murine model [37].   
 
5. Conclusions 
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Multi-parametric bioengineered tumour angiogenesis microenvironments developed within 
this study are able to more closely mimic in vivo models than 2D cultures. We anticipate 
these new biomimetic tumour microenvironments to provide a valuable new tool to answer 
intricate biological questions and improve our limited comprehension of the role of 
microenvironmental and vascular signals in cancer progression. Insights gained with 
additional explorations using this model may lead to the identification of new therapeutic 
targets and more effective treatment options for breast and prostate cancer. 
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Figures 
 
Figure 1. Multi-parametric hydrogels for the development of tumour angiogenesis 
microenvironments.  
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Figure 2. 3D microenvironment conditions result in tumour formation. MCF-7, MDA-MB-231, 
LNCaP and PC3 cells were cultivated within γ1 (~1500 Pa) starPEG-heparin hydrogels for 14 days. 
A) Relative metabolic activity of cells expressed as percentage of 2D tissue culture plastic control. B) 
Mean spheroid size as measured through Image J software. C) Left column displays extended focus 
confocal images of the 3D tumour microenvironment via phalloidin (red) and Hoechst (blue) 
immunostaining. Scale bar = 100 μm. Right column displays hypoxia (green) localization via 
pimonidazole staining. Scale bar = 50 μm. 
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Figure 3. Comparison of the 3D tumour microenvironment with Matrigel
TM
. A) Cellular 
morphology as shown by light microscopy. Scale bar = 100 μm. B) Immunofluorescent staining of 3D 
tumour microenvironment and Matrigel
TM
 cultures. Immunostaining shows phalloidin (red), Hoechst 
(blue) and targeted antibody (green). Scale bar = 50μm.  
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Figure 4. 3D tumour angiogenesis microenvironments after 14 days culture. A) Comparison of 
tumour angiogenesis microenvironments seeded as single cell tumours (left) or pre-grown spheroids 
(center) into soft hydrogels of approximately 200 Pa. Controls consisted of single cell tumours seeded 
into Matrigel
TM
 (right). Scale bars = 100 μm. B) Extended focus confocal images displaying phalloidin 
(red), Hoechst (blue) and CD31 (green) showing HUVEC and MSC to cancer cell interactions for each 
tumour cell type. Scale bars = 50 μm. C) Extended focus image (left) and a series of 3 z-stack 
confocal images showing an example of MCF-7 tumour angiogenesis interactions within the 
microenvironment. Scale bars = 150 μm. 
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Figure 5. Breast cancer tumour angiogenesis 3D microenvironment responsiveness to 
cytotoxic drug treatment. MCF-7 and MDA-MB-231 cells were cultured in 2D, 3D, or as a tri-culture. 
Cultures were exposed to drugs for 24 hours. Analysis was performed 3 days and 5 days post-
treatment. A) Light microscopy of untreated control, and highest concentration of anticancer drugs at 
5 days post-treatment. Scale bar = 100 μm. B) Relative tumour regression within tumour only 3D 
cultures relative to untreated control. Data is presented as mean ± standard deviation. C) PrestoBlue 
analyses of cultures 3 and 5 days post drug treatment. Data is presented as percentage untreated 
control (therefore 0 ng/mL of drug = 100%). Experiments were performed 3 times in triplicate. Data 
shown as mean ± standard error of the mean. Vertical asterisks indicate significance decrease from 
untreated control. 
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Figure 6. Prostate cancer tumour angiogenesis 3D microenvironment responsiveness to 
cytotoxic drug treatment. LNCaP and PC3 cells were cultured in 2D, 3D, or as a tri-culture. Cultures 
were exposed to drugs for 24 hours. Analysis was performed 3 days and 5 days post-treatment. A) 
Light microscopy of untreated control, and highest concentration of anticancer drugs at 5 days post-
treatment. Scale bar = 100 μm. B) Relative tumour regression within tumour only 3D cultures relative 
to untreated control. Data is presented as mean ± standard deviation. C) PrestoBlue analyses of 
cultures 3 and 5 days post drug treatment. Data is presented as percentage untreated control 
(therefore 0 ng/mL of drug = 100%). Experiments were performed 3 times in triplicate. Data shown as 
mean ± standard error of the mean. Vertical asterisks indicate significance decrease from untreated 
control. 
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Figure 7. Tumour microenvironment responsiveness to angiogenic inhibitor treatment. 3D 
Tumour only microenvironments (left column) and tumour angiogenesis tri-culture systems (center 
and right columns) were treated with Axitinib (VEGFR inhibitor), AMD3100 (SDF-1R inhibitor) or SU-
5402 (FGFR inhibitor) on Day 0 or Day 7 of culture. Cultures were grown for a further 7 days before 
metabolic activity was assessed via PrestoBlue assay. Data is presented as percentage of untreated 
control. Data shown as mean ± standard deviation (n=3). 
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Supplementary Figure 1. Tumour cell growth over 14 days within starPEG-heparin hydrogels. A) 
Hydrogels of three different stiffness were prepared, γ0.75 (~500 Pa), γ1.0 (~1500 Pa) and γ1.25 
(~3000 Pa). B) MCF-7, MDA-MB-231, LNCaP and PC3 cell lines were seeded at 10,000 cells per 20 
µl gel and grown for 14 days. PrestoBlue data is expressed as percentage of tissue culture plastic 
(TCP) metabolic activity. Data shown as mean ± standard error of the mean (n=4). Graphs on the 
right show average spheroid size within the hydrogels. γ0.75 gels degraded after 4-7 days.  
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Supplementary Figure 2. A) Tumour angiogenesis tri-cultures were cultivated within the 3D tumour 
microenvironment before analysis via atomic force microscopy at 1 hour post-seeding (Day 0) and 24 
hours post-seeding (Day 1). B) Response of HUVEC and MSC cultivated within 3D microenvironment 
to endogenous growth factors from Matrigel
TM
 co-culture (both hydrogel and Matrigel
TM
 in the same 
well of a culture plate). Left column displayed cultures without added VEGF, FGF-2 or SDF-1, while 
right column displays cultures with added VEGF, FGF-2 and SDF-1. Scale bars = 100 μm. 
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Table 1. Significance between high dose chemotherapy treatment of 2D tumour only cultures 
and 3D tumour angiogenesis tri-cultures. Student t-tests were performed between the three 
highest doses of each chemotherapy treatment between 2D and 3D tri-cultures using GraphPad 
Prism v6. Significance is presented as ns (not significant), * (p<0.05), ** (P<0.01), *** (p<0.001) and 
**** (p<0.0001). 
MCF-7 2D vs Tumour 
Angiogenesis 
Tri-culture 
 MDA-MB-231 2D vs Tumour 
Angiogenesis  
Tri-culture 
Epirubicin 
Dose 
(ng/mL) 
Day 3 Day 5  Epirubicin 
Dose 
(ng/mL) 
Day 3 Day 5 
400 * ns  400 ns ns 
2000 ns ns  2000 ns ns 
4000 * **  4000 * * 
Paclitaxel 
Dose (nM) 
   Paclitaxel 
Dose (nM) 
  
20 ns ns  20 ns ns 
100 ns ns  100 ns ns 
500 ns ns  500 ns ns 
 
LNCaP 2D vs Tumour 
Angiogenesis 
Tri-culture 
 PC3 2D vs Tumour 
Angiogenesis 
Tri-culture 
Doxorubicin 
Dose 
(ng/mL) 
Day 3 Day 5  Doxorubicin 
Dose 
(ng/mL) 
Day 3 Day 5 
400 ns *  400 ** * 
2000 ns ns  2000 ** ** 
4000 ns *  4000 ** ** 
Paclitaxel 
Dose (nM) 
   Paclitaxel 
Dose (nM) 
  
20 ns ns  20 *** **** 
100 ns ns  100 ** **** 
500 ** *  500 ** **** 
 
 
